A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma, Open-Angle Eye Diseases Glaucoma Ocular Hypertension

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Guangzhou, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of open-angle glaucoma or ocular hypertension
No use of Lumigan® in the past 3 months

Exclusion criteria

Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months

Treatment and study plan

0.03% Bimatoprost

Drug

0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.

Other names: LUMIGAN®

Primary outcomes

Change From Baseline in Intraocular Pressure (IOP) in the Study Eye

Time frame: Baseline, Week 5

IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Acronym: LOTUSDI

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2012
First posted: Dec 25, 2013
Registry last updated: Jul 21, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed